Research programme: chemokine receptor type 4 inhibitors: Pierre FabreAlternative Names: Anti-CXCR4 antibodies - Pierre Fabre Centre d’Immunologie; Project F50067 - Pierre Fabre Centre d’Immunologie
Latest Information Update: 01 Sep 2016
At a glance
- Originator Pierre Fabre Centre d'Immunologie
- Class Monoclonal antibodies
- Mechanism of Action CCR4 receptor antagonists; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 30 Aug 2016 Preclinical trials in Cancer in France (Parenteral) before August 2016 (Pierre Fabre Centre d’Immunologie pipeline, August 2016)